预约演示
更新于：2025-11-17
Atovaquone
阿托伐醌
更新于：2025-11-17
概要
基本信息
药物类型 小分子化药 |
别名 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone、Atovaquone (JAN/USP/INN)、Mepron Suspension + [14] |
作用方式 抑制剂 |
作用机制 电子传递复合物Ⅲ抑制剂 |
在研适应症 |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-11-25), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C22H19ClO3 |
InChIKeyKUCQYCKVKVOKAY-CTYIDZIISA-N |
CAS号95233-18-4 |
关联
24
项与 阿托伐醌 相关的临床试验NCT06624371
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
NCT05998135
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
JPRN-jRCTs031210557
A single-arm, phase II study to evaluate the effect of low-dose atovaquone on the prevention of pneumocystis pneumonia in patients with rheumatic diseases treated with corticosteroids
100 项与 阿托伐醌 相关的临床结果
登录后查看更多信息
100 项与 阿托伐醌 相关的转化医学
登录后查看更多信息
100 项与 阿托伐醌 相关的专利（医药）
登录后查看更多信息
1,850
项与 阿托伐醌 相关的文献（医药）2026-01-01BRAIN BEHAVIOR AND IMMUNITY
Systematic screening identifies medication and disease factors associated with schizophrenia risk
Article
作者: Israel, Ariel ; Merzon, Eugene ; Israel, Sarah ; Magen, Eli ; Stokar, Joshua ; Ashkenazi, Shai ; Vinker, Shlomo ; Weizman, Abraham
Schizophrenia (SCZ) is a severe psychiatric disorder with a complex and poorly understood etiology. Previous studies have linked Toxoplasma gondii infection to SCZ, though its clinical relevance remains uncertain. To identify factors associated with SCZ risk, we analyzed electronic health records from a national Israeli health provider, retrospectively comparing 3,273 individuals with SCZ to 32,730 matched controls. We systematically screened all medication purchases and medical diagnoses recorded from 10 years to 30 days before SCZ onset. Significant associations, adjusted for residual confounding, were further evaluated in the TriNetX network, where large propensity score-matched cohorts were compared for incident SCZ following medication exposure. Among all medication classes screened, strong protective associations were detected for specific antimicrobials, notably atovaquone/proguanil, clindamycin, and ophthalmic fluoroquinolones. Nonsteroidal anti-inflammatory drugs, particularly COX-2 inhibitors, were also linked to reduced SCZ risk, whereas neomycin, tramadol, and desmopressin were associated with increased risk. Key associations were confirmed within TriNetX with high statistical significance. These observational findings, reproduced across two national cohorts, are hypothesis-generating and may reflect multiple, non-exclusive mechanisms, including antimicrobial, anti-inflammatory, and microbiome-related pathways, with T. gondii elimination through antiprotozoal activity representing one compelling explanatory hypothesis that warrants further investigation.
2025-10-04Cureus Journal of Medical Science
A Case of Pneumocystis Pneumonia Caused by Long-Term Low-Dose Steroid Therapy
Article
作者: Suzuki, Keisuke ; Yoshida, Eriko ; Sasage, Hiroto ; Nakamura, Motoyasu ; Watanabe, Kenta ; Takaoka, Ryota ; Dohi, Kenji ; Suzuki, Satoshi
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. It typically occurs in patients with advanced HIV infection and severely reduced CD4+ T cell counts, but it is also seen in other immunocompromised hosts such as those receiving long-term corticosteroids, immunosuppressive agents, or chemotherapy. Common symptoms include progressive dyspnea, dry cough, and low-grade fever. In general, patients at risk for PCP who are receiving the equivalent of 20 mg/day or more of prednisolone for at least eight weeks are recommended to receive prophylactic trimethoprim-sulfamethoxazole (TMP-SMX) therapy. We report our experience of managing PCP in an 80-year-old man with a history of rheumatoid arthritis who had been receiving oral prednisolone 4 mg/day for 21 years. The patient was admitted to our hospital for rehabilitation due to disuse syndrome following surgery for aortic dissection. On hospital day one, the patient developed a fever. Oxygenation impairment was observed, prompting chest radiography and subsequent computed tomography (CT) imaging, which revealed reticular shadows and ground-glass opacities in both lung fields. These findings led to the suspicion of bacterial pneumonia and initiation of ceftriaxone therapy. By day four, his oxygen saturation dropped to 90% on room air, and laboratory tests showed a β-d-glucan level of 62.5 pg/ml. On day five, the antibiotic regimen was switched to meropenem, vancomycin, and TMP-SMX. Bronchoscopy was considered unsafe because of the patient's general condition, and sputum polymerase chain reaction (PCR) was performed instead, which was positive for Pneumocystis jirovecii. Based on the PCR results, clinical course, and imaging findings, a diagnosis of PCP was made. ST and atovaquone were administered for a total of three weeks, resulting in defervescence and significant improvement in oxygenation. Even low-dose corticosteroid therapy is associated with an increased risk of opportunistic infections, depending on the cumulative dose. Although our patient had been receiving only a low daily dose, the cumulative exposure indicated a high risk for infections such as PCP. In conclusion, our case experience suggests that in patients receiving long-term corticosteroid therapy, PCP and other opportunistic infections must be considered in the differential diagnosis of pneumonia, regardless of the daily corticosteroid dose received.
2025-10-01Lancet Rheumatology
Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention
Review
作者: Georgin-Lavialle, Sophie ; Jachiet, Vincent ; Ribier, Valentine ; Mekinian, Arsène ; Lacombe, Valentin ; Beck, David B ; Savic, Sinisa ; Dubée, Vincent ; Hadjadj, Jérôme ; Grayson, Peter C ; Terrier, Benjamin
Infections are increasingly recognised as a major cause of morbidity and mortality in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. We conducted a systematic review to characterise the infectious burden of VEXAS syndrome and propose preventive strategies. We included 57 studies (813 patients) showing that infections in patients with VEXAS syndrome were frequent, severe in 40-60% of cases, and fatal in 6-15% of cases. Pulmonary infections were most common, followed by cutaneous infections and bacteraemia. Opportunistic pathogens, such as Pneumocystis jirovecii, Legionella pneumophila, non-tuberculous mycobacteria, and varicella zoster virus, were frequently reported, even in patients not receiving immunosuppressive therapy, which suggests intrinsic immune dysfunction. Prophylaxis with co-trimoxazole (or other Pneumocystis prophylaxis, such as atovaquone or pentamidine) and valaciclovir should particularly be considered for patients at high risk of infection, including those receiving immunosuppressive therapy and those with lymphopenia, pMet41Val mutation, or previous severe or recurrent infections. Posaconazole might be appropriate in patients with neutropenia who are taking azacitidine. Vaccination against Streptococcus pneumoniae, varicella zoster virus, influenza, and SARS-CoV-2 is recommended. These data highlight the need to integrate infectious risk into VEXAS syndrome management and to evaluate preventive strategies in prospective studies.
100 项与 阿托伐醌 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺孢子菌肺炎 | 美国 | 1992-11-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV感染 | 临床3期 | 美国 | 2001-08-31 | |
| 恶性疟 | 临床2期 | 泰国 | 2011-09-01 | |
| 获得性免疫缺陷综合征 | 临床2期 | 美国 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床2期 | 比利时 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床2期 | 加拿大 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床2期 | 法国 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床2期 | 德国 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床2期 | 荷兰 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床2期 | 波多黎各 | 2001-08-31 | |
| 获得性免疫缺陷综合征 | 临床2期 | 英国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 21 | Standard of care radiotherapy+Atovaquone Oral Suspension (Dose Level 1 - 450 mg BD Atovaquone + Concurrent CRT) | 廠獵膚範築製蓋憲餘淵 = 廠範廠繭壓顧築願繭衊 壓鏇繭繭繭醖襯鹹夢廠 (範壓艱願淵繭膚簾艱築, 蓋醖憲醖壓夢範鹽膚繭 ~ 淵襯艱襯壓願餘蓋憲範) 更多 | - | 2024-11-25 | ||
Standard of care radiotherapy+Atovaquone Oral Suspension (Dose Level 2 - 600 mg BD Atovaquone + Concurrent CRT) | 廠獵膚範築製蓋憲餘淵 = 夢糧願淵網鑰鏇觸醖醖 壓鏇繭繭繭醖襯鹹夢廠 (範壓艱願淵繭膚簾艱築, 壓襯齋網選繭憲壓壓廠 ~ 夢醖餘襯製襯餘築範鹽) 更多 | ||||||
N/A | - | Atovaquone 750mg bd | 窪鏇淵製齋淵齋窪獵鹽(簾積積鑰製蓋顧蓋簾範) = 壓選襯夢觸窪築願壓築 選願獵壓鏇壓鏇鹽網壓 (壓繭憲壓繭壓獵築衊鏇, -58.2 ~ -4.4) | - | 2020-11-01 | ||
N/A | 26 | 顧衊顧夢膚鹹遞鹽窪繭(淵淵築淵憲壓築製顧製) = 艱顧鏇構鬱築繭繭夢獵 糧獵鑰鏇淵憲襯壓網顧 (齋簾襯鬱繭壓築鏇遞簾 ) | 积极 | 2008-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用